Pfenex (PFNX) Misses Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. QQQ
8. LDOS
9. AXP
10. AON

Go back to Pfenex (PFNX) Misses Q2 EPS by 5c

Pfenex Reports Second Quarter Results and Provides Business Update

August 8, 2018 4:05 PM EDT

SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfnex Expression Technology® to improve protein therapies for unmet patient needs. Using the patented Pfnex Expression Technology platform, the Company has created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Today Pfenex Inc. reported financial results for the second quarter ended June 30, 2018 and provided a business update.

The momentum in our business continues to build as we deliver on key milestones for our... More